Walk Ahead for a Brain Tumor Cure on Oct. 21

Thousands expected at annual event

Three women pose at walk ahead event

The ninth annual Walk Ahead for a Brain Tumor Cure is Sunday, Oct. 21, 2018 at Sawyer Point.

  • Registration begins at 7:30 a.m.
  • Timed 5K run begins at 8:30 a.m.
  • 5K walk begins at 9 a.m.
  • Wheelchair friendly 2K begins at 9 a.m.

Thousands of walkers and runners will support research and educational efforts of the University of Cincinnati Brain Tumor Center at the University of Cincinnati Gardner Neuroscience Institute.

Now nearly a decade in existence, Walk Ahead 2018 will have raised $2 million over its entire lifetime, following the 2018 event.

Brain tumors are not uncommon. More than 200,000 people are stricken with brain tumors in America every year. During the last two decades, the frequency of brain tumors has increased 22 percent overall and 55 percent in people over 65 years of age. The University of Cincinnati Brain Tumor Center is a regional destination for brain tumor patients, providing compassionate care while striving to find causes and cures. The funds raised through Walk Ahead advance the innovative research necessary to developing new treatments.

Register, volunteer or donate. 

Related Stories

1

Recent advances may speed time to endometriosis diagnosis

March 16, 2026

The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.

3

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.